Corcept Therapeutics (CORT) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Atmosphere Climate Change Environment Escape Forest Global Warming Hazard Life Cycle Materials Nature Offset Package Packaging Pandemic Raw Materials Waste Access Benefits Black California Consumer Privacy Act Charitable Charity Collective Bargaining Community Customer Customer Satisfaction Cybersecurity Data Privacy Data Security Death Demographic Disability Diversity Drug Pricing Employee Engagement Gender General Data Protection Regulation Health Care Healthcare Hire Hiring Human Resources Incident Injuries Injury LGBTQ Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Social Society Supplier Supply Chain Talent Training Union Volunteer Women Action Plan Activist Assessment Assurance Audit Board Oversight Bonus Class Action Lawsuit Classified Commitment Corporate Governance Corporate Purpose Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Mission Oversee Oversight Plaintiff Purpose R&D Reputation Reputational Research and Development Responsibility Responsible Special Meeting Strategy Supermajority Targets Tax Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 31, 2022, we held our annual meeting of stockholders to consider and vote on proposals: 1) to elect nine directors to hold office until our 2023 annual meeting of stockholders, 2) to approve the Corcept Therapeutics Incorporated Amended and Restated 2012 Incentive Award Plan, and 3) to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
A total of 106,249,716 shares of Corcept Therapeutics Incorporated common stock held by stockholders of record at the close of business on April 13, 2022 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 97,532,419. The voting on the three matters is set forth below:
Proposal 1 — Election of Directors. The following directors were elected to serve until our 2023 annual meeting of stockholders.

Director	For	Withheld	Broker Non-Votes

Gregg Alton	72,738,526	11,445,289	13,348,604
G. Leonard Baker, Jr.	70,597,281	13,586,534	13,348,604
Joseph K. Belanoff, M.D.	83,809,681	374,134	13,348,604
Gillian M. Cannon, Ph.D.	82,052,091	2,131,724	13,348,604
David L. Mahoney	72,563,105	11,620,710	13,348,604
Joshua M. Murray	83,865,037	318,778	13,348,604
Kimberly Park	81,854,209	2,329,606	13,348,604
Daniel N. Swisher, Jr.	72,184,474	11,999,341	13,348,604
James N. Wilson	80,854,416	3,329,399	13,348,604

Proposal 2 — The Corcept Therapeutics Incorporated Amended and Restated 2012 Incentive Award Plan was not approved.


For			39,228,147
Against			44,592,257
Abstain			363,411
Broker Non-Votes			13,348,604

Proposal 3 — The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022 was ratified.


For			96,415,192
Against			1,052,185
Abstain			65,042
Broker Non-Votes			N/A